Immunotherapy in melanoma patients with autoimmune disease
10.3760/cma.j.issn.1673-422X.2017.04.019
- VernacularTitle:合并自身免疫性疾病的黑色素瘤患者的免疫疗法
- Author:
Chengyu SUN
;
Yuqing XU
- Keywords:
Melanoma;
Immunotherapy;
Autoimmune disease
- From:
Journal of International Oncology
2017;44(4):310-312
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has become an important treatment for melanoma.The anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody or programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor is safe and effective for melanoma patients with autoimmune disease (AD).However, when such patients are treated with anti-CTLA-4 antibody or PD-1/PD-L1 inhibitors, their condition changes should be closely monitored to prevent and avoid possible AD progression and immune-related adverse events.
